91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
In this article from Fierce Biotech, Chris Smyth, President of 91黑料 Biotech outlines reasons for optimism in 2024, as the biotech sector looks to bounce back after several challenging years.
-
In this article from The Journal of mHealth, Chris Smyth, President of 91黑料 Biotech, dissects the challenges and opportunities discovered in 91黑料's recent biotech sector survey. He explores strategies for accelerating the drug development process, emphasising the potential of partnerships to strategically support biotech companies, how organisations are addressing the current funding challenges and the industry’s overall commitment to addressing unmet healthcare needs.
-
In this video interview with Fierce Biotech, Chris Smyth, President of 91黑料 Biotech, provides insight into the operating environment facing biotechs in 2024.
-
In this article from PM360, Chris Smyth, President of 91黑料 Biotech, summarises the main findings from the biotech sector survey and outlines the key implications for biotech including strategic collaboration, innovation and cost optimisation.
-
This article by Chris Smyth, President, 91黑料 Biotech, provides an overview of the recent 91黑料 biotech sector survey findings, and looks at the trend of biotech companies engaging earlier and more comprehensively with CROs to drive efficiencies and realise the full value of their R&D programs.
-
In this article, Brandon Early, SVP Project Delivery, outlines some of the key findings from the 91黑料 biotech sector survey of over 130 decision makers in small, mid-size, large biotech and VC organisations.
-
This article from Clinical Insider outlines 91黑料’s view that the demand for clinical trial services will increase in 2024, in addition to providing an overview of the results of the recent 91黑料 biotech sector survey, the findings of which suggest that biotech R&D spending is likely to increase.
-
This article from Fierce Biotech provides an overview of findings from the 91黑料 2023 biotech sector survey, which shows that despite cash struggles, 60% of the survey respondents anticipate their R&D spend to rise over the next one to two years.
-
Due diligence and beyond
Dr. Sandra Eagle outlines how due diligence has evolved from a discrete standalone technical assessment, to now being an integrated part of the holistic development continuum of an asset.
-
Brandon Early discusses how optimising trials designs at the earliest stages can help innovative biotech companies to maximise their available capital.
